All In Biotech

Drug Trial Radar · NCT07230730

A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Jan 13, 2026

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, and safety of SHR-1918 in reducing serum low-density lipoprotein cholesterol (LDL-C) and total triglycerides (TG) in patients with hyperlipidemia compared with placebo, and also includes To evaluate the effectiveness of SHR-1918 in reducing other lipid indicators in patients with mixed hyperlipidemia and to assess the safety of SHR-1918 in patients with mixed hyperlipidemia.

Conditions

  • Hyperlipidemia

Interventions

  • SHR-1918Drug

    SHR-1918

  • SHR-1918 placeboDrug

    SHR-1918 placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage change of serum LDL-C from baselineTime frame: Baseline and Week 24
  2. The percentage change in serum TG from baselineTime frame: Baseline and Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.